An Isogenic Human ESC Platform for Functional Evaluation of Genome-wide-Association-Study-Identified Diabetes Genes and Drug Discovery

Hui Zeng, Min Guo, Ting Zhou, Lei Tan, Chi Nok Chong, Tuo Zhang, Xue Dong, Jenny Zhaoying Xiang, Albert S. Yu, Lixia Yue, Qibin Qi, Todd Evans, Johannes Graumann, Shuibing Chen

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Genome-wide association studies (GWASs) have increased our knowledge of loci associated with a range of human diseases. However, applying such findings to elucidate pathophysiology and promote drug discovery remains challenging. Here, we created isogenic human ESCs (hESCs) with mutations in GWAS-identified susceptibility genes for type 2 diabetes. In pancreatic beta-like cells differentiated from these lines, we found that mutations in CDKAL1, KCNQ1, and KCNJ11 led to impaired glucose secretion in vitro and in vivo, coinciding with defective glucose homeostasis. CDKAL1 mutant insulin+ cells were also hypersensitive to glucolipotoxicity. A high-content chemical screen identified a candidate drug that rescued CDKAL1-specific defects in vitro and in vivo by inhibiting the FOS/JUN pathway. Our approach of a proof-of-principle platform, which uses isogenic hESCs for functional evaluation of GWAS-identified loci and identification of a drug candidate that rescues gene-specific defects, paves the way for precision therapy of metabolic diseases.

Original languageEnglish (US)
Pages (from-to)326-340
Number of pages15
JournalCell Stem Cell
Volume19
Issue number3
DOIs
StatePublished - Sep 1 2016

Fingerprint

Genome-Wide Association Study
Genetic Association Studies
Drug Discovery
Drug Repositioning
Glucose
Metabolic Diseases
Insulin-Secreting Cells
Type 2 Diabetes Mellitus
Genes
Homeostasis
Insulin
Cell Line
Mutation
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cell Biology

Cite this

An Isogenic Human ESC Platform for Functional Evaluation of Genome-wide-Association-Study-Identified Diabetes Genes and Drug Discovery. / Zeng, Hui; Guo, Min; Zhou, Ting; Tan, Lei; Chong, Chi Nok; Zhang, Tuo; Dong, Xue; Xiang, Jenny Zhaoying; Yu, Albert S.; Yue, Lixia; Qi, Qibin; Evans, Todd; Graumann, Johannes; Chen, Shuibing.

In: Cell Stem Cell, Vol. 19, No. 3, 01.09.2016, p. 326-340.

Research output: Contribution to journalArticle

Zeng, H, Guo, M, Zhou, T, Tan, L, Chong, CN, Zhang, T, Dong, X, Xiang, JZ, Yu, AS, Yue, L, Qi, Q, Evans, T, Graumann, J & Chen, S 2016, 'An Isogenic Human ESC Platform for Functional Evaluation of Genome-wide-Association-Study-Identified Diabetes Genes and Drug Discovery', Cell Stem Cell, vol. 19, no. 3, pp. 326-340. https://doi.org/10.1016/j.stem.2016.07.002
Zeng, Hui ; Guo, Min ; Zhou, Ting ; Tan, Lei ; Chong, Chi Nok ; Zhang, Tuo ; Dong, Xue ; Xiang, Jenny Zhaoying ; Yu, Albert S. ; Yue, Lixia ; Qi, Qibin ; Evans, Todd ; Graumann, Johannes ; Chen, Shuibing. / An Isogenic Human ESC Platform for Functional Evaluation of Genome-wide-Association-Study-Identified Diabetes Genes and Drug Discovery. In: Cell Stem Cell. 2016 ; Vol. 19, No. 3. pp. 326-340.
@article{40a0c1b8f6274351b12c3df94baa786d,
title = "An Isogenic Human ESC Platform for Functional Evaluation of Genome-wide-Association-Study-Identified Diabetes Genes and Drug Discovery",
abstract = "Genome-wide association studies (GWASs) have increased our knowledge of loci associated with a range of human diseases. However, applying such findings to elucidate pathophysiology and promote drug discovery remains challenging. Here, we created isogenic human ESCs (hESCs) with mutations in GWAS-identified susceptibility genes for type 2 diabetes. In pancreatic beta-like cells differentiated from these lines, we found that mutations in CDKAL1, KCNQ1, and KCNJ11 led to impaired glucose secretion in vitro and in vivo, coinciding with defective glucose homeostasis. CDKAL1 mutant insulin+ cells were also hypersensitive to glucolipotoxicity. A high-content chemical screen identified a candidate drug that rescued CDKAL1-specific defects in vitro and in vivo by inhibiting the FOS/JUN pathway. Our approach of a proof-of-principle platform, which uses isogenic hESCs for functional evaluation of GWAS-identified loci and identification of a drug candidate that rescues gene-specific defects, paves the way for precision therapy of metabolic diseases.",
author = "Hui Zeng and Min Guo and Ting Zhou and Lei Tan and Chong, {Chi Nok} and Tuo Zhang and Xue Dong and Xiang, {Jenny Zhaoying} and Yu, {Albert S.} and Lixia Yue and Qibin Qi and Todd Evans and Johannes Graumann and Shuibing Chen",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.stem.2016.07.002",
language = "English (US)",
volume = "19",
pages = "326--340",
journal = "Cell Stem Cell",
issn = "1934-5909",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - An Isogenic Human ESC Platform for Functional Evaluation of Genome-wide-Association-Study-Identified Diabetes Genes and Drug Discovery

AU - Zeng, Hui

AU - Guo, Min

AU - Zhou, Ting

AU - Tan, Lei

AU - Chong, Chi Nok

AU - Zhang, Tuo

AU - Dong, Xue

AU - Xiang, Jenny Zhaoying

AU - Yu, Albert S.

AU - Yue, Lixia

AU - Qi, Qibin

AU - Evans, Todd

AU - Graumann, Johannes

AU - Chen, Shuibing

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Genome-wide association studies (GWASs) have increased our knowledge of loci associated with a range of human diseases. However, applying such findings to elucidate pathophysiology and promote drug discovery remains challenging. Here, we created isogenic human ESCs (hESCs) with mutations in GWAS-identified susceptibility genes for type 2 diabetes. In pancreatic beta-like cells differentiated from these lines, we found that mutations in CDKAL1, KCNQ1, and KCNJ11 led to impaired glucose secretion in vitro and in vivo, coinciding with defective glucose homeostasis. CDKAL1 mutant insulin+ cells were also hypersensitive to glucolipotoxicity. A high-content chemical screen identified a candidate drug that rescued CDKAL1-specific defects in vitro and in vivo by inhibiting the FOS/JUN pathway. Our approach of a proof-of-principle platform, which uses isogenic hESCs for functional evaluation of GWAS-identified loci and identification of a drug candidate that rescues gene-specific defects, paves the way for precision therapy of metabolic diseases.

AB - Genome-wide association studies (GWASs) have increased our knowledge of loci associated with a range of human diseases. However, applying such findings to elucidate pathophysiology and promote drug discovery remains challenging. Here, we created isogenic human ESCs (hESCs) with mutations in GWAS-identified susceptibility genes for type 2 diabetes. In pancreatic beta-like cells differentiated from these lines, we found that mutations in CDKAL1, KCNQ1, and KCNJ11 led to impaired glucose secretion in vitro and in vivo, coinciding with defective glucose homeostasis. CDKAL1 mutant insulin+ cells were also hypersensitive to glucolipotoxicity. A high-content chemical screen identified a candidate drug that rescued CDKAL1-specific defects in vitro and in vivo by inhibiting the FOS/JUN pathway. Our approach of a proof-of-principle platform, which uses isogenic hESCs for functional evaluation of GWAS-identified loci and identification of a drug candidate that rescues gene-specific defects, paves the way for precision therapy of metabolic diseases.

UR - http://www.scopus.com/inward/record.url?scp=84981736275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981736275&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2016.07.002

DO - 10.1016/j.stem.2016.07.002

M3 - Article

C2 - 27524441

AN - SCOPUS:84981736275

VL - 19

SP - 326

EP - 340

JO - Cell Stem Cell

JF - Cell Stem Cell

SN - 1934-5909

IS - 3

ER -